Initiation of the pediatric Phase 3 program for XPHOZAH (tenapanor) in CKD-related hyperphosphatemia. Procedural milestone in the pediatric label-expansion path.
What’s at stake
XPHOZAH (tenapanor) is an oral small-molecule therapy developed by Ardelyx that reduces serum phosphorus in dialysis-dependent chronic kidney disease (CKD) by blocking the NHE3 sodium/hydrogen exchanger in the gut lining. In patients on dialysis, the kidneys can no longer excrete phosphorus, causing hyperphosphatemia that accelerates vascular calcification and cardiovascular mortality. Tenapanor acts locally in the gut without systemic absorption, closing the paracellular channels through which dietary phosphorus is absorbed; it is approved as a stand-alone or add-on to phosphate binders, with an ongoing pediatric label-expansion program.
No primer in glossary yet.
This event was extracted from a primary disclosure. The full chain of citations is in the disclosure trail below.
Competitive landscape
| Drug | Company | Modality | Mechanism | Phase | Next catalyst |
|---|---|---|---|---|---|
| olezarsen | IONS | oligonucleotide | ApoCIII antisense oligonucleotide | PDUFA · Dec 26 | |
| AMVUTTRAvutrisiran | ALNY | siRNA | TTR-targeting RNAi | PDUFA · Dec 26 | |
| plozasiran | ARWR | siRNA | APOC3-targeting RNAi | CONFERENCE · May 26 | |
| VERVE-102 | VERV | gene therapy | LNP-delivered base editor targeting PCSK9 | INTERIM · Nov 26 |
Disclosure trail
- May 6, 2026·-8368m agopinned · highest confidenceMED conf10-QQTRtop claimQ3'26
“We expect to initiate the pediatric Phase 3 program for XPHOZAH in the third quarter of 2026.”
conf 83%via llm